Is Rapport Therapeutics, Inc. Common Stock (RAPP) overvalued? · $532.9M cap
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
This page asks whether Rapport Therapeutics, Inc. Common Stock (RAPP) looks expensive on cached numbers — not a short thesis.
No cached income statement for RAPP, so there is no earnings base to call rich or cheap.
RAPP currently screens at market cap $532.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RAPP 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RAPP stock page for the full model, not this heading.
Not investment advice.